Artelo biosciences to present at the 6th cannabinoid-derived drug development summit on september 12th

Solana beach, calif., sept. 06, 2023 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that myles osborn, medicinal chemist at artelo biosciences, will be presenting at the 6th cannabinoid-derived drug development summit being held september 11-13, 2023 at the hilton boston back bay hotel in boston, ma.
ARTL Ratings Summary
ARTL Quant Ranking